E-Z-Em to market Pharmacyclics' Gadolite:
This article was originally published in Clinica
E-Z-Em has obtained exclusive North American marketing rights to Pharmacyclics' MRI oral contrast agent, Gadolite. US FDA approval for use of the agent in abdominal and pelvic imaging will be sought by Pharmacyclics this year. Phase III trials were completed earlier this year (see Clinica No 645, p 22). E-Z-Em, which has the option to negotiate additional marketing rights, will collaborate on development of Gadolite and other products using Pharmacyclics' technology. The two companies will share profits on net sales of Gadolite.